Cell Therapy Ltd. grants exclusive license for Japan to Daiichi Sankyo. Read More »

Cigna Corp., based in Bloomfield, Connecticut, has raised the bar in pharmaceutical incentives by entering into agreements with two major suppliers that calibrate costs according to patient response, directly linking fiscal conditions to improved outcomes. Read More »

Allergan and Gedeon Richter announce positive results of Venus I trial. Read More »

Allergan announces its schedule of presentations at the ASCRS Symposium & Congress in New Orleans. Read More »

Allergan to present data on overactive bladder, nocturia and ulcerative interstitial cystitis at the AUA meeting this weekend. Read More »

"LILETTA Access on the Front Line" to increase access to IUDs for U.S. military women. Read More »

CHMP issues positive opinion on Allergan's ENZEPI for patients with EPI Read More »

The collaborations will create tools to predict how type 2 diabetics will follow their medication plans. Read More »

Allergan to present results of its studies at the ARVO meeting next week. Read More »

Topokine is focused on topical medications to reduce fat; Allergen acquires XAF5 in the purchase. Read More »

Chronic migraine, limb spasticity and Alzheimer's are on the schedule at the Vancouver meeting. Read More »

Allergan, a worldwide leader in the development of treatments design to combat infectious diseases, has released new data from its anti-infective portfolio. Read More »

Allergan, a worldwide leading pharmaceutical company, and Sosei Group Corp. subsidiary, Heptares Therapeutics, have announced that Allergan Pharmaceuticals International Limited, an Allergan subsidiary, and Heptares have an agreement in place that will give Allegran exclusive worldwide licensing rights to a wide variety of novel subtype-selective muscarinic receptor agonists that are currently in development. Read More »

Sanofi and Regeneron Pharmaceuticals will be presenting new joint Phase 3 data from the clinical trial for the Praluent (alirocumab) Injection at the American College of Cardiology’s 65th Annual Scientific Session & Expo (ACC.16) in Chicago on April 2-4. Read More »

Allergan has announced that it has submitted an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for the approval of market Paclitaxel Protein-Bound Particles for Injectable Suspension, 100 mg/vial. Read More »

Advaxis has announced that data from its ADXS-HER2 dose-escalation study in canine osteosarcoma (OSA) has been published in Clinical Cancer Research, an online publication of the American Association for Cancer Research (AACR) on March 18. Read More »

Sanofi and Regeneron Pharmaceuticals recently announced that both companies strongly oppose the U.S. District Court jury decision for two patents involving Amgen antibodies designed to target PCSK9 (proprotein canvertase subtilisin/kexin type 9) that have been deemed valid. Read More »

Sanofi and Regeneron Pharmaceuticals announced that the Phase 3 study of monotherapies set to demonstrate the superiority of sarilumab to adalimumab when treating active rheumatoid arthritis (RA) has met its primary goal. Read More »

Merck, or MSD outside of the United States and Canada, has named Sanat Chattopadhyay as its new EVP and president of Merck Manufacturing Division (MMD). Read More »

Sanofi US and Regeneron Pharmaceuticals Inc. announced last week that the two companies will receive exclusive or preferred access to Praluent (alirocumab) injections from Humana for commercial and Medicare patients. Read More »